March 24, 2026 4:47pm
Duped over relief, conflagration (no war declared), oil, Ai and software jitters
My view, stay in a line of sight
RMi collects, curates, interprets and disseminates cell and gene therapy sector (C>) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision
Never leave a retail investor uninformed! It’s not always time to buy or sell; but it is time to KNOW why!
I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence! I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!
RMi Pre-opening; None, what was going to change my view, never SELL into a down market? – HOLD
I chose to speak-up when many analysts, brokers and commentators have shut-up!
What happened and some of the whys with the numbers behind … it’s NOT always about BUYs/SELLs … it’s about knowing when and what!
Tuesday: The Dow closed DOWN -84.41 points or -0.18%, the S&P closed DOWN -24.63 points or -0.37% while the Nasdaq closed DOWN -184.865 points or -0.84%
- Theme of the session: confusion has grown over how effective the talks to end the war
Tuesday’s (my) 40-company covered sector’s advance/decline line opened negative with 8 incliners, 30 decliners and 2 flats, ending with a negative close of 11 incliner, 27 decliners and 2 flats
Henry’omics: We need to more than consider the economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C>) sector
- Oil prices resumed their rally Tuesday after tumbling in the prior day. Global benchmark Brent crude futures added more than 4% to trade above $104 a barrel. West Texas Intermediate crude futures had jumped 4% to above $92 a barrel.
The CBOE Fear (VIX) index, Tuesday closed at 26.94, after Monday’s 26.46, Friday’s 26.78, Thursday’s 24.36, Wednesday’s 24.68 and last Tuesday’s 22.38
Metrics: Tuesday …
- The RUT was up +11.22 points or +0.45%,
- The XLV was up +0.02 points or +0.01%,
- The NBI was down -40.92 points or -0.73%;
- The XBI was down -2.16 points or -1.77%
- The IWM was up +1.37 or +0.55%;
- The IBB was down -1.05 points or -0.65%,
- The VIX was up +0.79 points or +3.02% at to 26.94
Q1/26 – March – 7 positive and 10 negative closes
- February – 1 holiday, 8 negative and 11 positive sessions
- January – 2 holidays, 2 neutral, 9 negative and 9 positive closes
Tuesday Closing UP (11 of 11)
- Alnylam Pharmaceuticals (ALNY +$1.39 after Monday’s -$5.51),
- AxoGen (AXGN +$0.86 after Monday’s +$0.97),
- Vericel (VCEL +$0.63),
- BioLife Solutions (BLFS +$0.53),
- Mesoblast (MESO +$0.30 after Monday’s -$0.34),
- Compass Therapeutics (CMPX +$0.29 after Monday’s -$0.11),
- Supernus Therapeutics (SUPN +$0.13 after Monday’s +$1.49),
- Moderna (MRNA +$0.06 after Monday’s -$0.10),
- Voyager Therapeutics (VYGR +$0.04),
- Sangamo Therapeutics (SGMO +$0.0165),
- Wave Life Sciences (WVE +$0.01 after Monday’s -$0.14),
Flat (3)
- Brainstorm Cell Therapeutics (BCLI)
- Harvard Apparatus RT (OTCQB: HRGN)
- Generation Bio (GBIO) – acquired
Tuesday’s Closing DOWN (10 of 27):
- Vertex (VRTX -$2.61 after Monday’s +$2.85),
- Lenz Therapeutics (LENZ -$1.97 after Monday’s +$0.52),
- Ultragenyx Pharmaceuticals (RARE -$1.77 after Monday’s +$0.40)
- BioNTech (BNTX -$1.60 after Monday’s -$0.86),
- Capricor Therapeutics (CAPR -$1.23 after Monday’s +$1.00,
- Beam Therapeutics (BEAM -$1.22 after Monday’s +$0.54),
- Ionis Pharmaceuticals (IONS -$1.11 after Monday’s -$0.20),
- IQVIA Holdings (IQV +$0.74 after Monday’s +$0.93),
- uniQure NV (QURE -$0.74),
- Regenxbio (RGNX -$0.53),
The Bottom Line: More of the … WHY
Digging through the ruble of share pricing on Tuesday. … I am STILL a wait and HOLD!
- US stocks resumed a slide on Tuesday as investors weighed new developments in Iran.
- After President Trump suggested the US and Iran were negotiations.
- While the Pentagon reportedly plans to send elite troops to the region in an effort to clear the Strait of Hormuz.
- Small caps remained barely positive, with the Russell 2000 holding on to a fractional gain, following Monday's 2.3% increase.
- U.S. oil prices on Tuesday resumed their climb, rising nearly 6% to around $93.05 a barrel. Brent crude, the international benchmark, advanced almost 5% to trade around $104.70 a barrel.
While: Think comparing financial econs …
- The 2-year Treasury yield spiked on Tuesday following a “weak” auction, according to BMO, which said there was less non-dealer bidding than average.
- The yield was last up more than 11 basis points at 3.944%. Additionally, the 10-year Treasury yield was more than 8 basis points higher at 4.42%.
Interesting quote: as I wrote hold and nibble, who will be judged stupid or reactionary?
Monday marked an “inflection point” for retail investors, according to VandaTrack analyst Ruta Prieskienyte. Everyday traders sold more than $20 M worth of single stocks on balance on Monday.
- Marking the 1st day of net selling since November 2023.
- Monday’s action built on a broader theme of retail participation in the market softening since the U.S.-Iran conflict began.
- “The trend since the start of March has been one of gradually receding retail participation, alongside systematic deleveraging and only modest buying from long-only and hedge fund investors on the other side”
- But while small investors pulled away, big money appeared to be racing in…
March – 4th week:
- 3/24 – Tuesday closed negative with 11 incliner, 26 decliners and 3 flats
- 3/23 - Monday closed positive with 26 incliners, 12 decliners and 2 flats
March – 3rd week
- 3/20 – Friday closed negative with 6 incliner, 33 decliners and 1 flat
- 3/19 – Thursday closed positive with 20 incliners, 18 decliners and 2 flats
- 3/18 – Wednesday closed negative with 3 incliner, 35 decliners and 2 flats
- 3/17 - Tuesday closed positive with 25 incliners, 14 decliners and 1 flat
- 3/16 - Monday closed positive with 27 incliners, 10 decliners and 3 flats
As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there – closed end funds” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!
Why do I keep repeating, framed in a different para, so investors can make the connection
The top three (3) performing in the session: Winners
- Tuesday: Alnylam Pharmaceuticals (ALNY), AxoGen (AXGN) and Vericel (VCEL)
- Monday: IQIA Holdings (IQV), Vericel (VCEL) and CRISPR Therapeutics (CRSP)
- Friday: Alnylam Pharmaceuticals (ALNY), uniQure NV (QURE) and Voyager Therapeutics (VYGR)
The worst three (3) in the session: Losers
- Tuesday: Lenz therapeutics (LENZ), Ultragenyx Pharmaceuticals (RARE) and Vertex (VRTX)
- Monday: Alnylam Pharmaceuticals (ALNY), uniQure NV (QURE) and Wave Life Sciences (WVE)
- Friday: Vertex (VRTX), Capricor Therapeutics (CAPR) and Vericel (VCEL)
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):
The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
